Cardlytics’ (CDLX) “Neutral” Rating Reaffirmed at Bank of America

Cardlytics (NASDAQ:CDLX)‘s stock had its “neutral” rating reissued by research analysts at Bank of America in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $11.00 target price on the stock. Bank of America‘s price target would suggest a potential upside of 34.06% from the company’s current price.

Several other brokerages have also recently weighed in on CDLX. Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 price target on shares of Cardlytics in a research note on Tuesday, June 11th. Northland Securities assumed coverage on shares of Cardlytics in a research report on Tuesday. They issued an “outperform” rating and a $14.00 target price for the company. Craig Hallum cut their price target on shares of Cardlytics from $18.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, May 9th. Northland Capmk upgraded Cardlytics to a “strong-buy” rating in a report on Tuesday. Finally, Lake Street Capital lifted their target price on Cardlytics from $13.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, March 15th. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Cardlytics has an average rating of “Moderate Buy” and a consensus price target of $12.67.

Cardlytics Trading Down 0.4 %

CDLX opened at $8.21 on Thursday. The stock has a market capitalization of $400.24 million, a P/E ratio of -1.86 and a beta of 1.67. The company has a current ratio of 2.13, a quick ratio of 2.13 and a debt-to-equity ratio of 1.30. Cardlytics has a 12 month low of $5.53 and a 12 month high of $20.52. The firm’s fifty day simple moving average is $10.64 and its 200 day simple moving average is $9.57.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.35) EPS for the quarter. The firm had revenue of $67.61 million during the quarter. Cardlytics had a negative net margin of 55.23% and a negative return on equity of 25.36%.

Insider Activity

In other news, insider Nicholas Hollmeyer Lynton sold 12,460 shares of Cardlytics stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $13.69, for a total value of $170,577.40. Following the completion of the sale, the insider now directly owns 71,355 shares in the company, valued at $976,849.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CEO Karim Saad Temsamani sold 43,129 shares of the stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $8.65, for a total transaction of $373,065.85. Following the sale, the chief executive officer now owns 385,530 shares in the company, valued at approximately $3,334,834.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Nicholas Hollmeyer Lynton sold 12,460 shares of the business’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $13.69, for a total transaction of $170,577.40. Following the transaction, the insider now owns 71,355 shares of the company’s stock, valued at $976,849.95. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 79,435 shares of company stock valued at $828,269. 4.40% of the stock is owned by company insiders.

Institutional Trading of Cardlytics

Several institutional investors and hedge funds have recently modified their holdings of CDLX. Price T Rowe Associates Inc. MD raised its stake in Cardlytics by 6.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company’s stock worth $432,000 after acquiring an additional 1,774 shares in the last quarter. Deutsche Bank AG grew its stake in shares of Cardlytics by 5.0% during the third quarter. Deutsche Bank AG now owns 43,992 shares of the company’s stock worth $726,000 after buying an additional 2,093 shares during the last quarter. Check Capital Management Inc. CA increased its holdings in shares of Cardlytics by 14.0% during the fourth quarter. Check Capital Management Inc. CA now owns 23,200 shares of the company’s stock worth $214,000 after buying an additional 2,850 shares in the last quarter. Brown Advisory Inc. lifted its stake in shares of Cardlytics by 1.7% in the 4th quarter. Brown Advisory Inc. now owns 199,633 shares of the company’s stock valued at $1,839,000 after acquiring an additional 3,257 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC grew its position in Cardlytics by 13.8% during the 1st quarter. Susquehanna Fundamental Investments LLC now owns 31,536 shares of the company’s stock worth $457,000 after acquiring an additional 3,836 shares during the last quarter. 68.10% of the stock is currently owned by institutional investors.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.